Effectiveness of fluticasone and budesonide in patients with moderate asthma

Clinical Drug Investigation

Volumn 16, Issue 2, 1998, Pages 117-123

  Steinmetz, Karl Otto ^a   Volmer, Timm ^b   Trautmann, Marion ^b   Kielhorn, Adrian ^b  

^a Glaxo Wellcome Germany ^*

^b Glaxo Wellcome GmbH and Co   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; FLUTICASONE;

ADULT; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; HEALTH CARE COST; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0031710965     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199816020-00004     Document Type: Article

References (29)

1. Weiss KB, Gergen PJ, Hodgson TA. An economic evaluation of asthma in the United Stales. N Engl J Med 1992; 326: 862-6
2. Mellis CM, Peat JK, Bauman AE, et al. The cost of asthma in New South Wales. Med J Aust 1991; 155: 522-8
3. Lenney W, Wells EJ, O'Neill BA. The burden of paediatric asthma. Eur Respir Rev 1994; 4: 49-62
4. Juniper EF, Guyatt GH, Ferrie PJ, et al. Measuring quality of life in asthma. Am Rev Respir Dis 1993; 147: 832-8
5. Sullivan S, Elixhauser A, Buist S, et al. National asthma education and prevention program working group report on the cost effectiveness of asthma care. Am J Respir Crit Care Med 1996; 154: 584-95
6. Townsend M, Feeny DH, Guyatt GH, et al. Evaluation of the burden of illness for pediatric asthmatic patients and their parents. Ann Allergy 1991; 67: 403-8
7. Nowak D, Volmer T, Wettengel R. Asthma bronchiale - eine Krankheitskostenanalyse. Pneumologie 1996; 50: 364-72
8. National Institutes of Health: Global initiatives for asthma - global strategy for asthma management and prevention. National Heart, Lung and Blood Institute Publication no. 95: 3659, 1996
9. British Thoracic Society, National Asthma Campaign, Royal College of Physicians in London. The British guidelines on asthma management: 1995 review and position statement. Thorax 1997; 52 Suppl. 1: S1-S21
10. Holliday SM, Faulds D, Sorkin EM. Inhaled fluticasone propionate: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma Drugs 1994 Feb; 47 (2): 318-31
11. Steinmetz K-O. Vergleich der Wirksamkeit und Verträglichkeit von Fluticason-propionat Dosieraerosol und Budesonid Pulverinhalat bei mittel-schwerem Asthma. Atemwegs Lungenkrankh. In press
12. Steinmetz K-O, Trautmann M. Efficacy of Fluticasone propionate (0.5 mg daily) via MD1 and Budesonide (1.2 mg daily) via Turbuhaler® in the treatment of steroid-naive asthmatics. Am J Respir Crit Care Med 1996; 153: A338
13. Statistisches Bundesamt: Statistisches Jahrbuch 1993 für die Bundesrepublik Deutschland. Wiesbaden, 1993
14. Bundesverband der Pharmazeutischen Industrie (BPI), Verband der Forschenden Arzneimittelhersteller (Eds). Rote Liste 1997. Aulendorf: Editio Cantor 1997
15. Nowak D, Volmer T, Wettengel R. Asthma bronchiale-eine Krankheitskostenanalyse. Pneumologie 1996; 50: 364-71
16. Booth PC, Capsey LJ, Langdon CG, et al. A comparison of the cost-effectiveness of alternative prophylactic therapies in the treatment of adult asthma. Br J Med Econ 1995; 8: 65-72
17. Volmer T, Wießmann KJ, Kielhorn A. Fluticasone propionate vs flunisolide in the treatment of steroid-naive patients with moderate asthma: a cost-effectiveness analysis of an open study. ATS 1998; 157 (3): A408
18. Volmer T, Weber HH, Kielhorn A. Cost-effectiveness of fluticasone propionate and flunisolide in the treatment of moderate asthma. ATS 1998; 157 (3): A406
19. Sculpher M, Buxton M. Episode-free days as end-points in economic evaluations of asthma therapy [letter]. Pharmacoeconomics 1994 Jan; 5(1): 78-9
20. Mellis CM, Peat JK, Woolcock AJ. The cost of asthma. Can it be reduced? Pharmacoeconomics 1993 Mar; 3 (3): 205-19
21. Barnes PJ, Jonsson B, Klim JB. The costs of asthma. Eur Respir J 1996; 9: 636-42
22. Donahue JG, Weiss ST, Livingston JM, et al. Inhaled steroids and the risk of hospitalization for asthma. JAMA 1997; 277: 887-91
23. Rutten-Van Mölken MPMH, Van Doorslaer EKA, Jansen MCC, et al. Costs and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 151: 975-82
24. Rutten-van Mölken MPMH, Van Doorslaer EKA, Jansen MCC, et al. Cost effectiveness of inhaled corticosteroid plus bronchodilator therapy versus hronchodilator monotherapy in children with asthma. Pharmacoeconomics 1993 Oct; 4 (4): 257-70
25. Liljas B, Ståhl E, Pauwels RA. Cost-effectiveness analysis of a dry powder inhaler (Turbuhaler®) versus a pressurised metered dose inhaler in patients with asthma. Pharmacoeconomics 1997 Aug; 12 (Pt. 2): 267-77
26. Mahajan P, Okamoto LJ, Schaberg A, et al. Impact of fluticasone propionate powder on health-related quality of life in patients with moderate asthma. J Asthma 1997; 34: 227-34
27. Goodwin B, Cox F, Noonan M, et al. The impact of inhaled fluticasone propionate (FP) 500 μg/day versus triamcinolone acetonide (TAA) 800 μg/day or placebo (PL) on general quality of life in adult asthmatics. Eur Respir J 1996; 9 Suppl. 23: 80s
28. Goodwin B, Cox F, Noonan M, et al. Inhaled fluticasone propionate (FP) 500 μg/day improves asthma-specific quality of life more than triamcinolone acetonide (TAA) 800 μg/day or placebo (PL). Eur Respir J 1996; 9 Suppl. 23: 80s
29. Lundback B, Bosh T. Quality of life improvements are greater in patients with severe asthma receiving inhaled fluticasone propionate 750 μg b.i.d. via Diskhaler® compared with Budesonide 800 μg b.i.d. via Turbuhaler®. Am J Respir Crit Care Med 1997; 155: A306